Nexalin Technology (NXL) Common Equity (2021 - 2026)

Nexalin Technology has reported Common Equity for 6 years, with the latest figure at $1.5 million in Q2 2026.

• On a quarterly basis, Common Equity fell 74.52% year-over-year to $1.5 million in Q2 2026; TTM through Jun 2026 was $1.5 million, a 74.52% decrease from a year earlier, with the FY2025 full-year figure at $3.7 million, up 1.96% from the prior year.
• Common Equity was $1.5 million for Q2 2026 at Nexalin Technology, down from $2.9 million in the prior quarter.
• The five-year high for Common Equity was $6.4 million in Q3 2022, with the low at -$2.2 million in Q2 2022.
• Average Common Equity over 5 years is $3.1 million, with a median of $3.5 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2026: Common Equity soared 425.74% in 2022, then tumbled 74.52% in 2026.
• Over 5 years, Common Equity stood at $5.5 million in 2022, then slumped by 41.47% to $3.2 million in 2023, then increased by 14.64% to $3.7 million in 2024, then rose by 1.96% to $3.7 million in 2025, then slumped by 59.46% to $1.5 million in 2026.
• The last three Common Equity figures came in at $1.5 million (Q2 2026), $2.9 million (Q1 2026), and $3.7 million (Q4 2025), per Business Quant data.